Insider Selling: John Lister Sells 3,500 Shares of DexCom Stock (DXCM)
DexCom (NASDAQ:DXCM) VP John Lister sold 3,500 shares of DexCom stock on the open market in a transaction dated Monday, July 14th. The shares were sold at an average price of $36.59, for a total value of $128,065.00. Following the transaction, the vice president now directly owns 114,158 shares in the company, valued at approximately $4,177,041. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
DexCom (NASDAQ:DXCM) traded down 1.59% during mid-day trading on Tuesday, hitting $36.41. The stock had a trading volume of 560,197 shares. DexCom has a 52 week low of $21.76 and a 52 week high of $49.83. The stock’s 50-day moving average is $37.36 and its 200-day moving average is $38.2. The company’s market cap is $2.728 billion.
DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, May 1st. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The company’s revenue for the quarter was up 59.1% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.33 earnings per share for the current fiscal year.
A number of research firms have recently commented on DXCM. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $39.60.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.